Rein Therapeutics, Inc. Amortization of Debt Discount (Premium)
Rein Therapeutics, Inc. (RNTX) reported Amortization of Debt Discount (Premium) of $1.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-14
- Rein Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2026-06-30 was $452.00K.
- Rein Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2026-03-31 was $623.00K.
- Rein Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2025-06-30 was $0.00.
- Rein Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2025-03-31 was $0.00.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month |
|---|---|---|
| 2026-06-30 | $452.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.07M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $623.00K 10-Q · filed 2026-05-15 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |